Weight variation in users of the once-a-month injectable contraceptive Cyclofem

Advances in Contraception

Volumn 14, Issue 4, 1998, Pages 185-192

  Bahamondes, L ^a   Diaz, J ^b   Petta, C ^a   Hall, P ^a   Marchi, N M ^l   Nakagava, H ^l   Pellini, E ^l   Rubin, J ^l   Neto, A A ^l   Araujo, F ^l   Monteiro, I ^l   Lavin P ^c,d,e,f,g   Bravo, C ^c,d,e,f,g   Morales, A ^c,d,e,f,g   Gutierrez, M C ^c,d,e,f,g   Bolivar, N ^c,d,e,f,g   Ramirez, M ^c,d,e,f,g   Alarcon M ^c,d,e,f,g   Zuniga M ^c,d,e,f,g   Silva, A ^c,d,e,f,g   Casas, G ^c,d,e,f,g   Wagner, M E ^c,d,e,f,g   Veliz C ^c,d,e,f,g   Ojeda, G ^h,i,j   Vargas, J C ^h,i,j   Medina, C E ^h,i,j   Londono J L ^h,i,j   Maradiegue, E ^k   Tavara L ^k   Guzman C ^k   Trelles, J ^k   Mauricio, J ^k   Rojas, C ^k   Goeznes, A ^k   more..

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Ministry Health Clinics   (Chile)

^d Ministry Health Clinics   (Chile)

^e Ministry Health Clinics   (Chile)

^f Ministry Health Clinics   (Chile)

^g Ministry Health Clinics   (Chile)

^h PROFAMILIA Clinics   (Colombia)

ⁱ PROFAMILIA Clinics   (Colombia)

^j PROFAMILIA Clinics   (Colombia)

^k Maria Auxiliadora Hospital   (Peru)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BODY WEIGHT; CONTRACEPTION; FEMALE; HEADACHE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; STATISTICAL ANALYSIS; WEIGHT GAIN;

ADULT; BODY WEIGHT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENSTRUAL CYCLE; WEIGHT GAIN;

EID: 6544234571     PISSN: 02674874     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006616617242     Document Type: Article

References (19)

1. Nasch H. Depo provera: a review. Contraception. 1975;12:377-93.
2. Ball MJ, Ashwell E, Gillmer MDG. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception. 1991;44:223-33.
3. Schwallie PC, Assenzo R. Contraceptive use - efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24:331-8.
4. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. Contraception. 1978;17:395-407.
5. Sangi-Haghpeykar H, Poindexter AN, Bateman L, Ditmore R Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227-33.
6. Hall P and World Health Organization. The introduction of Cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception. 1994;49:489-507.
7. World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bulletin of the World Health Organization. 1993;71:677-89.
8. Newton JR, d'Arcangues C, Hall PE. A review of "once-a-month" combined injectable contraceptives. J Obstet Gynaecol. 1994;14(Suppl. 1):S1-34.
9. Hall P, Bahamondes L, Diaz J et al. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru. Contraception 1997;56:353-9.
10. Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization, 1996.
11. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn. Oxford: Blackwell Scientific Publications, 1985.
12. Kesseru E, Aydinlik S, Etchepareborda JJ. Multicentred, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception 1994;50:329-37.
13. Haiba NA, El-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception. 1989;39:619-42.
14. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for the Regulation of Fertility. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg. 1. Contraceptive efficacy and side effects Contraception. 1986,34:223-35.
15. Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception. 1980;22:605-22.
16. Tanner JM The measurement of body fat in man. Proc Nutr Soc. 1959;18:148.
17. Garn SM. Anthropometry in clinical appraisal of nutritional status. Am J Clin Nutr. 1962;11:418.
18. Leiman G Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol. 1972;114.97-102.
19. Taneepanichskul S, Reinprayoon D, Khaossad P. Comparative study of weight change between long-term DMPA and IUD acceptors Contraception. 1998;58:149-51.